# EDGAR Filing Document

**Accession Number:** 0001534969
**File Stem:** 0001534969-25-000005
**Filing Date:** 2025-9
**Character Count:** 26381
**Document Hash:** 7b9fee6cd191b6ae7e29d78e7406c4dc
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001534969-25-000005.hdr.sgml**: 20250905

**ACCESSION NUMBER**: 0001534969-25-000005

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 42

**CONFORMED PERIOD OF REPORT**: 20250905

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20250905

**DATE AS OF CHANGE**: 20250905

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** SERA PROGNOSTICS, INC.
- **CENTRAL INDEX KEY:** 0001534969
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-MEDICAL LABORATORIES [8071]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 261911522
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40606
- **FILM NUMBER:** 251296783

**BUSINESS ADDRESS:**
- **STREET 1:** 2749 E. PARLEYS WAY
- **STREET 2:** SUITE 200
- **CITY:** SALT LAKE CITY
- **STATE:** UT
- **ZIP:** 84109
- **BUSINESS PHONE:** (801) 990-0520

**MAIL ADDRESS:**
- **STREET 1:** 2749 E. PARLEYS WAY
- **STREET 2:** SUITE 200
- **CITY:** SALT LAKE CITY
- **STATE:** UT
- **ZIP:** 84109

?xml version='1.0' encoding='ASCII'? 8-K

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549**

------

## FORM 8-K

------

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported):** September 05, 2025<br>

------

Sera Prognostics, Inc.

**(Exact name of Registrant as Specified in Its Charter)**

------

---

| | | |
|:---|:---|:---|
| Delaware | 001-40606 | 26-1911522 |
| **(State or Other Jurisdiction<br>of Incorporation)** | **(Commission File Number)** | **(IRS Employer<br>Identification No.)** |
| 2749 East Parleys Way<br>Suite 200 |  |  |
| Salt Lake City**,** Utah |  | 84109 |
| **(Address of Principal Executive Offices)** |  | **(Zip Code)** |

---

**Registrant's Telephone Number, Including Area Code:** (801) 990-0520<br>

Not Applicable

**(Former Name or Former Address, if Changed Since Last Report)**

------

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Securities registered pursuant to Section 12(b) of the Act:**

---

| | | |
|:---|:---|:---|
| **<br>Title of each class** | **Trading<br>Symbol(s)** | **<br>Name of each exchange on which registered** |
| Class A Common Stock, $0.0001 par value per share | SERA | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

## Item 7.01 Regulation FD Disclosure.
On September 5, 2025, Sera Prognostics, Inc. (the "Company") posted a new investor presentation to its corporate website. This presentation was also shared at the H.C. Wainwright 27th Annual Global Investment Conference on September 5, 2025 at 7 a.m. ET. A copy of the investor presentation is filed as Exhibit 99.1 hereto and incorporated by reference herein.

The information contained in Item 7.01, including Exhibit 99.1 furnished herewith, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities under that section, nor shall it be deemed incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, or into any filing or other document pursuant to the Exchange Act, except to the extent required by applicable law or regulation.

## Item 9.01 Financial Statements and Exhibits.
(d) Exhibits

---

| | |
|:---|:---|
| **Exhibit Number** | **Description** |
| 99.1 | [<u>Investor presentation to be posted on September 5, 2025.</u>](sera-ex99_1.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
|  |  |  | **SERA PROGNOSTICS, INC.** |
| Date: | September 5, 2025 | By:  | /s/ Austin Aerts |
|  |  |  | Austin Aerts<br>Chief Financial Officer |

---

------

## Exhibit 99.1

![Slide 1](sera-ex99_1s1.jpg)

September 2025 We are redefining pregnancy care to reduce the burden of preterm birth Exhibit 99.1

------

![Slide 2](sera-ex99_1s2.jpg)

This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation, including statements regarding our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans and objectives of management, are forward-looking statements. The words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. The company has no obligation to provide any updates to these forward-looking statements, even if its expectations change, whether as a result of new information, future events or otherwise, except as required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. Further information on potential factors, risks and uncertainties that could affect operating and financial results is included in the company's Registration Statement on Form S-1, most recent Annual Report on Form 10-K, and/or subsequent Forms 10-Q, including in each case under the heading RISK FACTORS, and in the company's other filings with the SEC. The information in this presentation should be considered in conjunction with a review of the company's filings with the SEC including the information in the company's Registration Statement on Form S-1, most recent Annual Report on Form 10-K, and/or subsequent Forms 10-Q, under the heading MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIALCONDITION AND RESULTS OF OPERATIONS. Safe Harbor Statement

------

![Slide 3](sera-ex99_1s3.jpg)

Our vision is to become a global leader in high-value women's health diagnostics. We'll do this by taking a holistic approach to providing pivotal information to providers and patients—simultaneously enabling better health for moms and babies while improving the economics of healthcare delivery. Our Bold Ambition We can do better for women's health. TOGETHER

------

![Slide 4](sera-ex99_1s4.jpg)

Reference: 1. Osterman MJK, Hamilton BE, Martin JA, Driscoll AK, Valenzuela CP. Births: Final Data for 2022. Natl Vital Stat Rep. 2024 Apr;73(2):1-56. PMID: 38625869 2 Martin JA, Osterman MJK. Increases in neonatal intensive care admissions in the United States, 2016–2023. NCHS Data Brief. 2025 Mar;525 3.marchofdimes.org/peristats/data?reg=99&top=3&stop=362&slev=1&obj=1 Usher in a new era of personalized pregnancy care through predictive diagnostics Use proteomics-based testing for women's health, with PreTRM® as our flagship blood-based predictor of spontaneous preterm birth risk PreTRM is the only clinically validated test available for early prediction of premature birth and is verified by 8 independent clinical studies CORPORATE OVERVIEW THE NEED/CHALLENGE THE SOLUTION POSITIONED FOR COMMERCIAL INFLECTION $108.5M Cash, cash equivalents, and marketable securities as of June 30, 2025. Cash position extends through 2028 to support reaching seminal revenue inflection point With ~$30M annual operating spend, strong balance sheet allows Sera to push full steam ahead on commercialization Full PRIME data publication and publication of sub analyses coming soon Ongoing progress in engaging Medicaid plans in targeted states with prior PreTRM clinical study experience, with one state pilot program already launched Opportunity to address $25.2 billion economic cost of preterm birth in the US3 Turning Data Into Better Maternal & Neonatal Outcomes 1 in 10 babies are born too soon1 National Vital Statistics Data: Infants were more likely to be admitted to a NICU in 2023 than in 2016, the percentage of infants admitted rose from 8.7% to 9.8%, according to CDC2 US has a D Rating from March of Dimes as it pertains to premature birth3

------

![Slide 5](sera-ex99_1s5.jpg)

THE Need

------

![Slide 6](sera-ex99_1s6.jpg)

THE US HAS A PREMATURE BIRTH PROBLEM And identification isn't getting better National Vital Statistics Data: Infants were more likely to be admitted to a NICU in 2023 than in 2016, according to the Centers for Disease Control. The percentage of infants admitted rose from 8.7% to 9.8% FROM 2013-20233 PRETERM BIRTH RATES IN THE US ROSE FROM 9.4% to 10.4% MARCH OF DIMES References: Martin JA, Osterman MJK. Increases in neonatal intensive care admissions in the United States, 2016–2023. NCHS Data Brief. 2025 Mar;525. DOI: https://dx.doi.org/10.15620/cdc/174581.

------

![Slide 7](sera-ex99_1s7.jpg)

HEALTH CARE COSTS OVER 7 YEARS Health Cost & Implications PREMATURE BIRTH LEADS TO 18X+ HIGHER BIRTH COST OF NEWBORNS Extremely Premature < 28 weeks Risk of death, long NICU stay, respiratory issues, decreased organ development, infections Premature < 32 weeks Respiratory issues, significant NICU stay, feeding challenges, temperature regulation, under development Full Term 37-40 weeks No associated conditions References: 1.Phibbs CS, et al. Birth Hospitalization Costs and Days of Care for Mothers and Neonates in California, 2009-2011. J Pediatr. 2019 Jan; 204:118-125.e14 2.Beam et al, Estimates of healthcare spending for preterm and low-birthweight infants in a commercially insured population: 2008-2016, Journal of Perinatology (2020) 40:1091–1099. - Preterm births account for 61% of neonatal costs for in-hospital deliveries 3. Full term cost source: https://www.healthsystemtracker.org/brief/health-costs-associated-with-pregnancy-childbirth-and-postpartum-care/ 4. Inflation calculator: https://www.bls.gov/data/inflation_calculator.htm Up to $344,355 $64,815 $18,865 AVERAGE DELIVERY CARE COST $30,889 \| ~7X Higher Costs $11,799 \| ~3X Higher Costs $4,165

------

![Slide 8](sera-ex99_1s8.jpg)

THE MAJORITY OF PREGNANT WOMEN who deliver prematurely are not identified using current methods Reference: 1. Everyday Health Group Pregnancy & Parenting Insights, Bump Day Survey 2022; Q: "At your first prenatal appointment, what written materials did your doctor provide you with?" Saade GR, et al. Development and validation of a spontaneous preterm delivery predictor in asymptomatic women. Am J Obstet Gynecol. 2016;214(5):633.e1-24. Data on file. SMFM Consult Series #70: Management of short cervix in individuals without a history of spontaneous preterm birth Biggio, Joseph American Journal of Obstetrics & Gynecology, Volume 231, Issue 2, B2 - B13 Only 20% OF PREGNANT MOTHERS REPORTED RECEIVING INFORMATION ON PRETERM LABOR RISK AT THEIR 1st PRENATAL APPOINTMENT 1 81% MISSED 8% Short Cervix 11% Prior Preterm Birth % OF SPONTANEOUS PRETERM BIRTHS IDENTIFIED THROUGH SCREENING TRADITIONAL SCREENING METHODS 100% of EXPECTANT MOTHERS

------

![Slide 9](sera-ex99_1s9.jpg)

PRODUCT AND Science

------

![Slide 10](sera-ex99_1s10.jpg)

THE PURPOSE Predictive test to detect biomarkers in the blood before symptoms arise WHAT IT MEASURES Risk of developing a condition, and biological effect HOW IT WORKS Uses advanced technologies (mass spectrometry) to analyze proteins and reveals patterns of protein expression and modification THE SCIENCE What is a proteomic test? Measures types & quantities of proteins present in a sample Reference: https://www.healthcaredive.com/spons/proteomic-tests-empower-precision-medicine/635232/

------

![Slide 11](sera-ex99_1s11.jpg)

BLOOD-BASED BIOMARKERS Specific proteins are associated with preterm birth risk IGFBP4 Insulin-like Growth Factor Binding Protein-4 Nutrient Delivery Reference: Saade GR, Boggess et al. Development and validation of a spontaneous preterm delivery predictor in asymptomatic women. Am J Obstet Gynecol 2016;214(5):633 e1–633 e24.©2025 Sera Prognostics, Inc. All rights reserved. PreTRM, Sera Prognostics and their logos are trademarks or registered trademarks of Sera Prognostics, Inc. in the United States. SHBG Sex Hormone Binding Globuline Signals Inflammation Discovered by Sera Prognostics in partnership with 13 Universities and Medical Institutions

------

![Slide 12](sera-ex99_1s12.jpg)

EVEN IF SHE LACKS EVIDENT RISK FACTORS Determine a Mom's risk of spontaneous preterm birth to improve outcomes NOT HIGHER RISK

------

![Slide 13](sera-ex99_1s13.jpg)

Results delivered in an average of five days from a CLIA-certified, CAP-accredited lab Blood sample kits are provided for testing during 180/7-206/7 weeks with prepaid shipment to Sera's lab Sample collection can be performed by staff and aligns with preexisting appointments©2025 Sera Prognostics, Inc. All rights reserved. PreTRM, Sera Prognostics and their logos are trademarks or registered trademarks of Sera Prognostics, Inc. in the United States. PreTRM SEAMLESSLY INTEGRATES AND COMPLEMENTS A WOMEN'S HEALTH CLINIC WORKFLOW

------

![Slide 14](sera-ex99_1s14.jpg)

Pregnancies identified as higher risk by the PreTRM Test are at increased risk for\*: Communicates a patient's risk of spontaneous preterm birth & helps physicians engage with patients TEST REPORT Spontaneous preterm birth Severe adverse neonatal outcomes Longer neonatal hospital length of stay Reference: Burchard J, et al. Clinical Validation of a Proteomic Biomarker Threshold for Increased Risk of Spontaneous Preterm Birth and Associated Clinical Outcomes: A Replication Study. J. Clin. Med. 2021, 10, 5088. doi: 10.3390/jcm10215088. Available at https://www.mdpi.com/2077-0383/10/21/5088 Final

------

![Slide 15](sera-ex99_1s15.jpg)

Evidence ROBUST CLINICAL

------

![Slide 16](sera-ex99_1s16.jpg)

Sera Drives Strategic Advantage to Deliver Clear Insights Biobank of Blood Samples Rich Portfolio of Evidence Demographic & Geographic Diversity Advanced Mass Spectrometry Artificial Intelligence & Machine Learning Global Dataset 20,000 pregnant women 11+ Published Studies; PRIME Pending Broad sample collection across U.S. population North America, Europe, Asia and Africa 300+ proteins analyzed Discovering important predictors EXCLUSIVE DATA ASSETS Early risk prediction such as preterm birth or preeclampsia, before symptoms manifest Improving health outcomes by identifying high-risk individuals and implementing targeted interventions Shared decision-making by empowering patients to make informed decisions regarding prenatal care Reduced healthcare costs through improvements in the health of the baby and reducing the need for the NICU Research advancements to help understand the biology of pregnancy Technology Platform

------

![Slide 17](sera-ex99_1s17.jpg)

THE PRETRM® TEST IS THE ONLY CLINICALLY VALIDATED TEST AVAILABLE FOR EARLY PREDICTION OF PREMATURE BIRTH PAPR Validation Study1 (n=5501, 11 centers) The PreTRM® Test is highly predictive of spontaneous preterm birth with a single blood draw during 180/7 through 206/7 weeks of gestation2 Three Independent Studies (discovery, verification, validation) reported in a large, multi-center trial Published as Editor's Choice article in American Journal of Obstetrics & Gynecology (May 2016) References: 1. Saade GR, et al. development and validation of spontaneous preterm delivery predictor in asymptomatic women. Am J Obstet Gynecol. 2016;214:633e1-24. 2. Burchard, J., et al. Better Estimation of Spontaneous Preterm Birth Prediction Performance through Gestational Age Dating. J. Clin. Med. 2022, 11, 2885. doi.org/10.3390/jcm11102885

------

![Slide 18](sera-ex99_1s18.jpg)

PRIME ABSTRACT The Randomized Controlled Trial Involved: 19 U.S. sites, including community practices and university-based or -associated medical centers Enrolled 5018 patients Presented at SMFM Annual Meeting 2025 From November 2020 – December 2023 AVERT STUDY The Historically Controlled Trial Involved: ChristianaCare Hospital (Newark, DE) Enrolled 1873 patients in the prospective arm compared to 10,000 historical controls Published in Diagnostics From June 2018 – September 2020 References: Hoffman MK, Kitto C, Zhang Z, Shi J, Walker MG, Shahbaba B, Ruhstaller K. Neonatal Outcomes after Maternal Biomarker-Guided Preterm Birth Intervention: The AVERT PRETERM Trial. Diagnostics. 2024; 14(14):1462. https://doi.org/10.3390/diagnostics14141462 Iriye, B.K. et al. Neonatal Impact of Prematurity Risk Biomarker Screening with Targeted Interventions: A Multicenter Randomized Controlled Trial. Presented at the Society for Maternal-Fetal Medicine Annual Pregnancy Meeting, Friday, January 31, 2025 (Abstract LB05). Multiple studies have demonstrated an effective approach to managing patients identified as higher risk with the PreTRM® Test PRIME ABSTRACT & AVERT STUDY

------

![Slide 19](sera-ex99_1s19.jpg)

PreTRM® Test shown in clinical validation studies to be more effective in reducing neonatal impacts than current measures Number (of mothers) Needed to Screen to prevent NICU admission: comparison between widely adopted screening vs PreTRM: lower number indicates greater efficiency Transvaginal Ultrasound Cervical Length + Progesterone to prevent NICU Admission1 150 Demonstrated in AVERT study3 ~4 Glucose screening test to prevent NICU Admission2 50 Number Needed to Screen for PreTRM to prevent 1 NICU day Sera PreTRM risk screening test to prevent NICU Admission 40 References: 1. Am J Obstet Gynecol. 2016 February ; 214(2): 235–242. doi:10.1016/j.ajog.2015.09.102. 2.JAMA. 2021;326(6):531-538. doi:10.1001/jama.2021.11922. 3. Data on file The number of patients needed to screen (NNS) to improve a clinical outcome is a convenient and widely used metric that informs both the economic and clinical impact of a screening test: AVERT STUDY The lower the NNS the better The NNS for established evidence-based tests recommended by the professional societies can be compared to PreTRM's screen-and-treat approach Just 4 moms need to be screened to prevent 1 NICU day stay More than 3x more efficient than ultrasound MOMS MOMS MOMS

------

![Slide 20](sera-ex99_1s20.jpg)

THE PRIME ABSTRACT Prematurity Risk Assessment Combined With Clinical Interventions for Improving Neonatal OutcoMEs PRIME Most Recent Evidence Shows Efficacy Across Different Populations A pioneering clinical trial assessing the efficacy of the PreTRM Test and preventive interventions in lowering the occurrence of adverse pregnancy outcomes. Achievement of a primary endpoint resulted in the early termination of the study.

------

![Slide 21](sera-ex99_1s21.jpg)

PRIME ABSTRACT + AVERT STUDY DEMONSTRATED HIGH CLINICAL UTILITY Studies Show PreTRM Test Significantly Improves Neonatal Outcomes LOWER NEONATAL MORBIDITY & MORTALITY 20% reduction in neonatal morbidity and mortality DECREASE IN NICU ADMISSIONS AND LENGTH OF STAY There was a 22% decrease in NICU admissions and an 8% reduction in length of stay INCREASE IN GESTATIONAL AGE The odds of delivery before 35 weeks decreased by 35% COST SAVINGS FROM PRETRM SCREENING Only 4 women needed to be screened with PreTRM to prevent 1 day in the NICU Reference: Iriye, B.K. et al. Neonatal Impact of Prematurity Risk Biomarker Screening with Targeted Interventions: A Multicenter Randomized Controlled Trial. Presented at the Society for Maternal-Fetal Medicine Annual Pregnancy Meeting, Friday, January 31, 2025 (Abstract LB05).

------

![Slide 22](sera-ex99_1s22.jpg)

EVIDENCE-BASED, TARGETED INTERVENTIONS FROM PRIME ABSTRACT & AVERT STUDY Clear direction on managing higherrisk pregnanciescomplementary with guidelines Low-Dose Aspirin (81 mg) Taken orally daily until 366/7 weeks gestation Vaginal Progesterone (200 mg) Administered daily as a 200 mg micronized progesterone suppository until 366/7 weeks' gestation Care Management Weekly phone calls are made by a trained, registered nurse References: Hoffman MK, Kitto C, Zhang Z, Shi J, Walker MG, Shahbaba B, Ruhstaller K. Neonatal Outcomes after Maternal Biomarker-Guided Preterm Birth Intervention: The AVERT PRETERM Trial. Diagnostics. 2024; 14(14):1462. https://doi.org/10.3390/diagnostics14141462 Iriye, B.K. et al. Neonatal Impact of Prematurity Risk Biomarker Screening with Targeted Interventions: A Multicenter Randomized Controlled Trial. Presented at the Society for Maternal-Fetal Medicine Annual Pregnancy Meeting, Friday, January 31, 2025 (Abstract LB05).

------

![Slide 23](sera-ex99_1s23.jpg)

PATHWAY TO Commercialization

------

![Slide 24](sera-ex99_1s24.jpg)

Ushers in a new era of personalized pregnancy care THE PRETRM® TEST

------

![Slide 25](sera-ex99_1s25.jpg)

WITH PRIME PUBLICATION We Are Entering Commercialization Stage Follows Key Milestones (Guidelines, Reimbursement) Market Adoption % R&D SERA FOUNDED 2025 PRIME STUDY EXPECTED Broad Market Adoption Clinical Validation & Evidence Generation Targeted Adoption INFLECTION POINT ILLUSTRATIVE Revenue TODAY Next Phase Guideline Inclusion & Payer Coverage

------

![Slide 26](sera-ex99_1s26.jpg)

KEY 12-24 MONTH REVENUE ACCELERATION INITIATIVES Geographic Focus: Investment in driving volume Additional Key Account Managers & Payer Staff Continue institutional (large hospitals and IDN) conversations, armed with PRIME data Pilots focus on state level Medicaid programs Develop individualized programs tailored to each local Medicaid population where PreTRM is encouraged for the entire patient population with focus on key outcome metrics Develop individualized programs tailored to institution where PreTRM is encouraged for the entire physician community of the institution with focus on key outcome metrics Add sales resources when deals are closed to educate and encourage adoption Expand these programs to additional states through: Ecosystem Engagement: Building density of adoption Focusing sales efforts on priority target physicians and their practices: Those who have participated in our clinical trials Early adopters who have expressed interest in and have tried PreTRM Expand to physicians who are locally influenced by innovators and early adopters Add sales resources in geographies of these groups to educate and encourage further adoption in additional physician groups More direct state by state outreach begin with 6 and expand Additional efforts with insurer administrators Add research resources in geographies of these groups to capture data on effectiveness of Medicaid pilots Pathway to Reaching Commercial Inflection OUR FOCUS

------

![Slide 27](sera-ex99_1s27.jpg)

Illustrative impact for example small insurance plan 95% Confidence Interval Cumulative Net Impact Key assumptions: Covered lives: 812,000 Pregnancies/year: 8,607 Eligible for test: 88%; Screen Positive: 24% Intervention acceptance: 65% Cost: Test=$750 Cost of intervention=$1,200 Savings per person screened: $4,234/ 52w Break-even: Weeks 48-56 (varies based on cost of care rates across states) Health Economic Data REACHING PAYERS WITH WEEKS CUMULATIVE BUDGET IMPACT ($) MILLIONS Model based on PRIME abstract outcomes applied to 1M covered lives in a commercial plan to identify savings from PreTRM testing of moms over time Source: Model to be presented at ISPOR EUROPE 2025, Nov 2025

------

![Slide 28](sera-ex99_1s28.jpg)

Reaching Moms with Premature Birth Education WEEK 15 EMAIL PreTRM.comJAN 01 – AUG 04 REACH OF US PREGNANT WOMEN 80% MONTHLY VISITORS 1.1MM 93% REACH OF FIRST TIME MOMS EVERYDAYHEALTH DIGITAL PARTNERSHIP 2025 SESSIONS: 161,309 2024 SESSIONS: 72,404

------

![Slide 29](sera-ex99_1s29.jpg)

Leadership Team THE

------

![Slide 30](sera-ex99_1s30.jpg)

Sera Leadership Zhenya LindgardtPresident & CEO Former VP of Platform & Customer Engagement, Uber Technologies Former Senior Partner & Managing Director, The Boston Consulting Group Former CEO, The Commons Project Foundation MBA, Harvard University Former VP, Finance & Corporate Controller, Sera Former finance team member, Myriad Former auditor, Ernst & Young LLP Master of Accounting University of Utah; CPA Austin AertsChief Financial Officer Former National Precision Oncology General Manager, Commercial team Former VP, US Oncology & Customer Service Lee AndersonChief Commercial Officer Jay Boniface, Ph.D. Chief Scientific Officer Robert G. Harrison Chief Information Officer Benjamin Jackson General Counsel Paul Kearney, Ph.D Chief Data Officer Michael Foley, M.D. Medical Advisor Doug Roach VP of Commercial Angie Fox VP of Clinical Operations Nikki Martin VP of Quality & Regulatory Jennifer Cohrs Head of Marketing Jennifer Zibuda Head of Investor Relations

------

![Slide 31](sera-ex99_1s31.jpg)

Educate Providers. Empower Moms. HELP Babies. Advance Science. Elevate Care. Reach Maternity Deserts. Inform Payers. Evoke Change. TOGETHER, WE CAN DO BETTER PRESENT-105 / 08-25